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Abstract
Background—Clinical, pathological and genetic overlap between sporadic frontotemporal 
dementia (FTD), Alzheimer’s disease (AD) and Parkinson’s disease (PD) has been suggested; 
however, the relationship between these disorders is still not well understood. Here we evaluated 
genetic overlap between FTD, AD and PD to assess shared pathobiology and identify novel 
genetic variants associated with increased risk for FTD.
Methods—Summary statistics were obtained from the International FTD Genomics Consortium, 
International PD Genetics Consortium and International Genomics of AD Project (n>75 000 cases 
and controls). We used conjunction false discovery rate (FDR) to evaluate genetic pleiotropy and 
conditional FDR to identify novel FTD-associated SNPs. Relevant variants were further evaluated 
for expression quantitative loci.
Results—We observed SNPs within the HLA, MAPT and APOE regions jointly contributing to 
increased risk for FTD and AD or PD. By conditioning on polymorphisms associated with PD and 
AD, we found 11 loci associated with increased risk for FTD. Meta-analysis across two 
independent FTD cohorts revealed a genome-wide signal within the APOE region (rs6857, 3′-
UTR=PVRL2, p=2.21×10−12), and a suggestive signal for rs1358071 within the MAPT region 
(intronic=CRHR1, p=4.91×10−7) with the effect allele tagging the H1 haplotype. Pleiotropic SNPs 
at the HLA and MAPT loci associated with expression changes in cis-genes supporting 
involvement of intracellular vesicular trafficking, immune response and endo/lysosomal processes.
Conclusions—Our findings demonstrate genetic pleiotropy in these neurodegenerative diseases 
and indicate that sporadic FTD is a polygenic disorder where multiple pleiotropic loci with small 
effects contribute to increased disease risk.
INTRODUCTION
Frontotemporal dementia (FTD) is a neurodegenerative disorder characterised by 
progressive impairment of behaviour, cognition and executive function or language.1 Recent 
converging evidence suggests clinical, pathological and genetic overlap between FTD and 
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other common neurodegenerative diseases including Alzheimer’s disease (AD) and 
Parkinson’s disease (PD).
From a clinical perspective, FTD and AD can sometimes be difficult to distinguish at onset 
or during disease progression:2 non-cognitive manifestations such as mood changes, 
psychosis and variable social conduct can characterise the initial phases of AD patients.3 
Similarly, cognitive dysfunctions such as changes in abstract thinking or poor judgement, 
planning and difficulty in completing tasks become evident in either condition as the disease 
progresses.4 This might partially reflect the fact that FTD and AD are associated with 
progressive impairment of similar brain circuits (frontal, prefrontal or temporal lobes and/or 
subcortical regions).5 Of note, among the primary progressive aphasia (PPA) cases in FTD, 
logopenic progressive aphasia (LPA) has been suggested as an atypical early presentation of 
AD.6 In addition, the subtype called FTD and parkinsonism linked to chromosome 17 
(FTDP-17)—linked to mutations in the microtubule-associated protein tau (MAPT)7 and 
progranulin (GRN) genes8—shows parkinsonian-like syndrome,9 while dementia features 
can be found in up to 30–80% of PD cases (Parkinson’s Disease Dementia (PDD)) in later 
stages of the disease.10
From a pathological perspective, abnormal intracellular accumulation of the tau protein is 
seen in FTD and AD.11 Additionally, TDP-43 pathology has been reported in AD and FTD 
at different disease stages,12 and in some rare PD cases associated with variability in 
leucine-rich repeat kinase 2 (LRRK2).13
From a genetic perspective, distinct genetic and genome-wide scale studies have suggested 
potential genetic overlap between FTD, AD and PD at specific loci. The MAPT gene on 
chromosome 17 has been extensively investigated in FTD11 and has been recently 
implicated in AD14 and PD,15 suggesting that tau pathology might jointly contribute to FTD, 
AD and PD. In addition, genome-wide association studies (GWAS) have revealed that 
common genetic variants within the HLA region on chromosome 6 increase risk for FTD,16 
AD17 and PD.18
Evaluating genetic overlap between complex traits is based on the concept that gene(s) or 
genetic variant(s) can influence more than one distinct phenotype (=genetic pleiotropy).19 
Availability of large-scale genetic data sets (eg, genome-wide summary statistics) is a key to 
estimate the level of genetic overlap, or genetic pleiotropy, across diverse traits including 
groups of related disorders.20
We have recently developed methods to evaluate genetic pleiotropy across different 
disorders (identifying novel genetic variants associated with various conditions including 
multiple sclerosis and AD).142122 In the current work, we sought to apply these methods 
taking advantage of existing large-scale genetic data (ie, summary statistics) for FTD,16 
AD23 and PD24 to identify genetic overlap, that is, pleiotropic effects, across these 
neurodegenerative disorders.
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MATERIALS AND METHODS
Participant samples
We evaluated complete summary statistics ( p values and ORs) from GWAS data of 
clinically diagnosed FTD,16 AD23 and PD.24 We used AD-GWAS summary statistic data 
from the International Genomics of AD Project (IGAP Stage 1), which consisted of 17 008 
AD and 37 154 controls with genotyped or imputed data at 7 055 881 SNPs (see table 1 for 
additional details).23 We obtained PD-GWAS summary statistic data from the International 
Parkinson’s Disease Genomics Consortium (IPDGC) consisting of 5333 cases and 12 019 
controls with genotyped and imputed data at 7 689 524 SNPs (see table 1 for additional 
details).24
We examined FTD summary statistic GWAS data (discovery+ replication phase) from the 
International FTD-Genomics Consortium (IFGC).16 As our discovery cohort, we used the 
IFGC phase I cohort (table 1), consisting of 2154 FTD cases and 4308 controls with 
genotyped and imputed data at 6 026 384 SNPs.16 To replicate our findings from the 
discovery analyses using IFGC phase I, we assessed the p values of pleiotropic SNPs 
(conditional FDR<0.05; see the ‘Statistical analysis’ section) within the IFGC phase II 
sample. The IFGC phase II sample consisted of 1372 FTD cases and 5094 controls 
genotyped using a partially custom-designed Illumina NeuroX chip (see table 1 for 
details).16 The IFGC multicenter GWAS has been described in detail elsewhere.16 Briefly, 
44 international research groups contributed samples to this two-stage clinical FTD-GWAS. 
We evaluated genetic data from patients clinically diagnosed with behavioural variant FTD 
(bvFTD), semantic dementia (SD), progressive non-fluent aphasia (PNFA) and FTD with 
motor neuron disease (FTD-MND). As described in the original study, we excluded any 
cases with clinically diagnosed LPA, progressive supranuclear palsy (PSP) or corticobasal 
degeneration (CBD). In this study, MAPT and GRN mutation carriers were excluded 
whereas individuals with C9orf72 expansions were not excluded because this locus was 
identified subsequent to original sample collection. The relevant institutional review boards 
or ethics committees approved the research protocol of the individual GWAS used in the 
current analysis, and all human participants gave written informed consent.
Statistical analysis
Using recently developed statistical methods to evaluate pleiotropic effects, we evaluated 
single nucleoide polymorphysms (SNPs) associating with FTD, AD and PD. These methods 
have been described in extensive detail in a number of recent publications.141722 Briefly, for 
given associated phenotypes A and B, pleiotropic enrichment of phenotype A with 
phenotype B exists if the proportion of SNPs or genes associated with phenotype A 
increases as a function of increased association with phenotype B. To assess enrichment, we 
constructed fold-enrichment plots of nominal −log10(p) values for all FTD-SNPs and a 
subset of SNPs determined by the significance of their association with PD and AD. In fold-
enrichment plots, the presence of enrichment is reflected by an upward deflection of the 
curve for phenotype A if the degree of deflection from the expected null line is dependent on 
the degree of association with phenotype B. To assess for polygenic effects below the 
standard GWAS significance threshold, we focused the fold-enrichment plots on SNPs with 
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nominal −log10(p)<7.3 (corresponding to p value>5×10−8). The enrichment can be directly 
interpreted in terms of true discovery rate (TDR=1−false discovery rate [FDR]).22
To identify specific loci involved in FTD and AD or FTD and PD, we computed conjunction 
FDR.17 Conjunction FDR, denoted by FDRtrait1& trait2, is defined as the posterior probability 
that a SNP is null for either phenotype or both simultaneously, given the p values for both 
traits are as small, or smaller, than the observed p values. A conservative estimate of the 
conjunction FDR is given by the maximum statistic in taking the maximum of FDRtrait1|trait2 
and FDR trait2|trait1.17 We used an overall FDR threshold of<0.05, which means five expected 
false discovery per hundred reported. Additionally, we constructed Manhattan plots based on 
the ranking of conjunction FDR to illustrate the genomic location of the pleiotropic loci.17
To identify specific FTD loci, we computed conditional FDR.1422 The standard FDR 
framework derives from a model that assumes the distribution of test statistics in a GWAS 
can be formulated as a mixture of null and non-null effects, with true associations (non-null 
effects) having more extreme test statistics, on average, than false associations (null effects). 
The conditional FDR is an extension of the standard FDR, which incorporates information 
from GWAS summary statistics of a second phenotype to adjust its significance level. The 
conditional FDR is defined as the probability that a SNP is null in the first phenotype given 
that the p values in the first and second phenotypes are as small as, or smaller, than the 
observed ones. It is important to note that ranking SNPs by standard FDR or by p values 
both give the same ordering of SNPs. In contrast, if the primary and secondary phenotypes 
are related genetically, conditional FDR re-orders SNPs and results in a different ranking 
than that based on p values alone. We used an overall FDR threshold of <0.05, which means 
five expected false discovery per hundred reported. Additionally, we constructed Manhattan 
plots based on the ranking of conditional FDR to illustrate the genomic location of the 
pleiotropic loci. In all analyses, we controlled for the effects of genomic inflation by using 
intergenic SNPs.1422 Detailed information on fold-enrichment and conditional Q-Q plots, 
Manhattan plots and conditional FDR can be found in prior reports.1422
For loci with conditional FDR<0.05, we performed a fixed effects, inverse variance 
weighted meta-analysis across the discovery and replication FTD cohorts (IFGC phases I 
and II, total n=3526 FTD cases and 9402 healthy controls) using the R package meta (http://
CRAN.R-project.org/package=meta).25 Briefly, the fixed effects, inverse variance weighted 
meta-analysis summarises the combined statistical support across independent studies under 
the assumption of homogeneity of effects. Individual study β estimates (log ORs) are 
averaged, weighted by the estimated SE.
Expression quantitative trait loci
For the expression quantitative trait loci (eQTL) analyses, we used data generated within the 
Braineac (http://www.braineac.org) and GTEx (http://www.gtexportal.org/home/) projects. 
Briefly, in braineac, eQTL data were generated from 101 neuropathologically defined 
controls in the following 10 brain regions: cerebellar cortex, frontal cortex, hippocampus, 
medulla (specifically inferior olivary nucleus), occipital cortex (specifically primary visual 
cortex), putamen, substantia nigra, thalamus, temporal cortex and intralobular white matter. 
In GTEx, eQTL data were available for the following 10 brain regions: anterior cingulate 
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cortex (BA24; n=72), caudate (basal ganglia; n=100), cerebellar hemisphere (n=89), 
cerebellum (n=103), cortex (n=96), frontal cortex (BA9; n=92), hippocampus (n=81), 
hypothalamus (n=81), nucleus accumbens (basal ganglia; n=93) and putamen (basal ganglia; 
n=82).
Each eQTL was within ± 1 MB of each SNP, and the significance threshold was p<1×10−5 
as per website curators.
RESULTS
Polygenic enrichment in FTD as a function of AD and PD
We observed enrichment for FTD-SNPs (IFGC phase I) across different levels of 
significance of association with AD and PD (figure 1). For progressively stringent p value 
thresholds of FTD-SNPs (ie, increasing values of nominal −log10PFTD≥6), we found 140-
fold and 120-fold pleiotropic enrichment as a function of AD (−log10PAD≥3.0) and PD 
(−log10PPD≥3.0) SNPs, respectively (figure 1). Although decreased in magnitude, we 
observed a similar pattern of enrichment for AD-SNPs and PD-SNPs conditional on FTD-
SNPs suggesting symmetric genetic overlap between the three neurodegenerative diseases 
(see online supplementary figure S1).
Conjunction FDR identifies shared FTD loci
At a conjunction FDR<0.05, we identified 11 SNPs that were associated with FTD and AD 
or PD (figure 2A and table 2). These included rs405509 (chromosome 19; intergenic; closest 
gene= APOE; conjunction trait=AD; min conjunction FDR=0.0052) and rs9268877 
(chromosome 6; intergenic; closest gene=HLA-DRA; conjunction trait=PD; min 
conjunction FDR=0.048). We also found two pleiotropic loci in the MAPT haplotype-
region, namely rs199528 (chromosome 17; intronic=WNT3; conjunction trait=PD; min 
conjunction FDR=0.018) and rs1358071 (chromosome 17; intronic=CRHR1; conjunction 
trait=PD; min conjunction FDR=0.02). We detected additional shared loci between FTD and 
PD on chromosomes 4 (rs7664889, intronic=SCARB2), 10 (rs676768, intronic=VWA2), 12 
(rs10784359, intronic= SLC2A13), 13 (rs2893253; intergenic; closest gene=EFNB2) and 18 
(rs12964543, intronic=ZNF532) (table 2).
Conditional FDR identifies novel FTD loci
To identify novel SNPs associated with FTD, we ranked IFGC phase I FTD-SNPs 
conditional on their genetic association with AD and PD (conditional FDR), particularly 
focusing on those SNPs that did not reach genome-wide significant levels in the previous 
FTD-GWAS. At a conditional FDR <0.05, we found 13 novel FTD susceptibility loci: 11/13 
polymorphisms were available for replication purposes within the IFGC2 cohort (7 actual 
SNPs and 4 proxies with linkage disequilibrium (LD) r2≥0.7 and within 500 kb distance 
from the reference SNP (based on HapMap 22/21)) (figure 2b, table 3). Then, meta-analysis 
across IFGC phase I and II cohorts revealed one genome-wide significant locus ( p<5×10−8): 
rs6857 on chromosome 19 (3’-UTR=PVRL2; conditioning trait=PD; reference allele=T; 
OR=1.34; 95% CI 1.23 to 1.45; p=2.21×10−12) (table 3, figures 3A and 4B). We also found 
one suggestive locus (at p<5×10−7) on rs1358071 within the MAPT region on chromosome 
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17 (intronic=CRHR1; conditioning trait=PD; reference allele=A; OR=1.19; 95% CI 1.11 to 
1.27; p=4.91×10−7) (table 3, figures 3B and 4B).
Expression quantitative trait loci
We evaluated potential biological relevance for each of the identified conjunction and 
conditional FDR SNPs (rs7664889, rs9268877, rs676768, rs10784359, rs2893253, 
rs199528, rs1358071, rs12964543, rs405509, rs4417745, rs1328032, rs2446406, rs7184882, 
rs6857, rs302665 and rs10507789) in human brain tissues assayed for genome-wide gene 
expression. There were 20 eQTLs in the Braineac data set, while data extracted from GTEx 
indicated up to 144 significant eQTLs (table 4). These were driven by rs199528 and 
rs1358071 (chr 17; MAPT-haplotype locus) and by rs9268877 (chr 6; HLA locus). No 
eQTLs were found for rs405509 and rs6857 (chr19; APOE locus).
The eQTL data from Braineac and GTEx were cross-supportive in different brain regions, 
including frontal and temporal cortices, jointly indicating influence on expression levels of 
LRRC37A2, KANSL1, LRRC37A4 and CRHR1 for rs199528 and rs1358071; conversely, 
changes in expression of HLA-DPA1 (from Braineac in frontal cortex), and HLA-DRB1 and 
HLA-DQA2 (from GTEx in subcortical regions and cerebellum) were evident for rs9268877 
(table 4).
DISCUSSION
The current work shows that several genetic markers are jointly associated with increased 
risk for FTD, AD and PD. By leveraging recently developed and validated genetic methods, 
our findings indicate potential shared genetic architecture among these neurodegenerative 
diseases and suggest the polygenic nature of sporadic FTD where multiple pleiotropic loci 
with small effect size contribute to increased disease risk. To the best of our knowledge, this 
is the first large-scale study assessing genetic overlap between sporadic FTD and AD, and 
sporadic FTD and PD.
Using the conjunction FDR (which identifies loci jointly associated with two traits), we 
found eight polymorphisms specific to FTD-PD and one to FTD-AD; through the 
conditional FDR (which leverages secondary phenotypes, eg, AD and PD, to improve 
statistical power for gene discovery) we identified 13 novel FTD associated loci. Of note, all 
nine conjunction FDR loci were also detected in the conditional FDR analyses supporting 
the notion that the shared polymorphisms increase risk for developing sporadic FTD. Across 
all analyses, we found notable relevance for the HLA, MAPT and APOE regions.
Building on prior work implicating the involvement of the immune system in PD26 and 
AD,17 we found that rs9268877, on chromosome 6, intergenic between HLA-DRA and 
HLA-DRB5, is a shared marker between FTD and PD. The risk allele of this SNP was 
robustly associated with changes in expression of HLA-DPA1 (increased expression), HLA-
DRB1 (increased expression) and HLA-DQA2 (decreased expression) in brain tissues. 
HLA-DPA1 is an HLA class II α chain paralogue presenting peptides derived from 
extracellular proteins;27 this is of particular relevance as impairment of clearance of 
extracellular debris might increase risk of developing a neurodegenerative condition,28 
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including FTD and PD. While HLA-DRB1 has functions similar to HLA-DPA1, HLA-
DQA2 belongs to the HLA class II α chain family located in intracellular vesicles: it plays a 
central role in the peptide loading of MHC class II molecules and releasing the class II-
associated invariant chain peptide (CLIP) molecule from the peptide-binding site. This 
prevents the binding of self-peptide fragments prior to MHC II localisation within the 
endolysosome.29 Taken together, these data support and further elucidate details about the 
role of immune system and endolysosomal processes in FTD and PD.
Our results also point to the MAPT region as jointly involved in PD and FTD through two 
SNPs on chromosome 17 mapping to WNT3 (wingless-type MMTV integration site family 
member 3; rs199528) and CRHR1 (corticotropin releasing hormone receptor 1; rs1358071). 
The risk alleles of both markers, which tag the H1 MAPT-haplotype (figure 4a), are 
associated with robust expression changes of LRRC37A2 (decreased expression), KANSL1 
(decreased expression), LRRC37A4 (increased expression) and CRHR1 (decreased 
expression). The LRRC37A (leucine-rich repeat containing 37 member) genes encode 
plasma membrane proteins that pass from the Golgi to the endoplasmic reticulum (ER) and 
extracellular areas through vesicle transport30 reiterating that intracellular vesicle trafficking 
is a sensitive and potentially vulnerable process in the brain. The KANSL1 (KAT8 
regulatory NSL complex subunit 1) gene encodes a nuclear protein targeting the DNA and 
involved in histone acetylation with the MLL1 and NSL1 complexes: disruption, mutations 
or haploinsufficiency of this gene have been associated with the 17q21.31 microdeletion 
syndrome.31 CRHR1 encodes a G protein-coupled receptor for neuropeptides involved in 
diverse physiological processes including stress and immune responses.32 Overall, these data 
strongly suggest that the H1 MAPT-haplotype contributes to increased risk for FTD and PD 
and its effect is likely mediated by modulating changes in the expression profiles of 
functionally important cis-genes.
We found evidence for involvement of the APOE region in FTD. We detected a genome-
wide significant association signal in sporadic FTD for rs6857 (3′UTR in PVRL2; p 
value=2.21×10−12) and identified rs405509, intergenic between TOMM40 (translocase of 
outer mitochondrial membrane 40) and APOE (apolipoprotein E), as jointly associated with 
FTD and AD. Rs6857 and rs405509 are in linkage equilibrium (LE; r2=0.1) and are part of 
two separate haplotypes (figure 4b): (1) one spanning 12 kb (including 13 SNPs 
[rs142042446, rs12972156, rs12972970, rs34342646, rs283811, rs283815, rs71352238, 
rs184017, rs2075650, rs34404554, rs11556505, rs778934950 and rs59007384] with r2~0.8) 
and encompassing PVRL2 and TOMM40 for rs6857 (haplotype a), and (2) one spanning 14 
kb (including 10 SNPs [rs157584, rs71337246, rs7157588, rs7157590, rs1160985, 
rs760136, rs741780, rs1038025, rs34215622 and rs7259620] with r2 ~0.8) and 
encompassing TOMM40 and APOE for rs405509 (haplotype b). Our data indicate that 
rs6857 increases risk of FTD, while this was not the case for rs405509. No SNP within 
either haplotype (a or b) was functionally associated with cis-regulatory effects. A large 
body of evidence implicates APOE as a strong genetic risk factor for AD. Whether it is a 
genetic modiffer of disease risk with non-AD neurodegenerative diseases is still unclear. In 
this respect, several studies in the literature have highlighted this locus as a potential risk 
factor, with variable effect size, for a variety of conditions including vascular dementia 
(VD), amyotrophic lateral sclerosis (ALS), PD and dementia with Lewy bodies (DLB).33 
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Although early work did not find a clear association between the APOE locus and FTD,34 
more recent studies suggest that it might associate with FTD risk35–37 and accelerate 
frontotemporal brain atrophy.38 Given potential overlap between patients diagnosed with 
clinical FTD and AD,39 it is unclear whether the current findings reflect a genuine 
association with FTD or might be inflated by subtle presence of AD or FTD cases in either 
original study cohort. Nonetheless, these data raise the question whether the detected 
PVRL2 SNP tags an FTD-specific risk disease haplotype: future work will be required to 
further characterise the potential role of this locus—in particular, haplotype a—in FTD.
We also detected several pleiotropic loci between FTD and PD, in addition to HLA, MAPT 
and APOE. The marker on chr 4, rs7664889, is intronic to the SCARB2 (scavenger receptor 
class B member 2) gene that encodes a glycoprotein locating to the membrane of lysosomes 
and endosomes further supporting the notion of impacted endolysosomal tracts in FTD and 
PD. The marker on chromosome 12, rs10784359 maps to the intronic region of SLC2A13 
(solute carrier family 2 member 13) a gene which is part of the extended locus that includes 
LRRK2 indicating that this region may also mediate FTD risk.40
Some limitations might apply to studies of this kind. Particularly, in the original works, the 
diagnoses of FTD, AD and PD were established clinically. This has the potential to 
introduce subtle clinical overlap across cohorts, thus assessments in large pathology 
confirmed cohorts is the next valuable and warranted step to take. However, it must be 
acknowledged that such ad hoc cohorts are currently not yet available.
Considered together with prior work, our results overall are a first step in the process of 
decrypting common underpinnings of FTD, AD and PD: they suggest that a subset of 
genetic markers in the HLA and MAPT-H1 regions (and potentially the APOE cluster) 
might be jointly involved in these neurodegenerative disorders. In the case of the HLA and 
MAPT loci, differentially expressed genes in distinct brain regions might account for the 
clinical and phenotypic differences observed across these disorders.41 Of note, the relevant 
pleiotropic SNPs that we found in the HLA and MAPT regions do appear to exert their 
effect by influencing expression changes in cis-genes involved in immune response, 
endolysosomal processes, intracellular vesicular trafficking and DNA/chromatin-associated 
metabolism, further supporting the notion of involvement of these processes in 
neurodegenerative disease, including FTD.42 More work will be needed to further 
characterise our pleiotropic signals, which might hold promise in the future for developing 
global preventive and therapeutic strategies for FTD, AD and PD.
In summary, we here identified (1) genetic overlap between FTD and AD and FTD and PD 
and (2) novel loci influencing FTD pathobiology with small effect size illustrating that a 
substantial polygenic component contributes to FTD risk.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Fold-enrichment plots of enrichment versus nominal −log10 p values (corrected for inflation) 
in FTD below the standard GWAS threshold of p<5×10−8 as a function of significance of 
association with AD (A) and PD (B) and at the level of −log10(p)≥0, −log10(p)≥1, −log10(p)
≥2 corresponding to p≤1, p≤0.1 and p≤0.01, respectively. Blue line indicates all SNPs. AD, 
Alzheimer’s disease; FTD, frontotemporal dementia; GWAS, genome-wide association 
studies; PD, Parkinson’s disease.
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Figure 2. 
‘Conjunction’ (A) and ‘conditional’ (B) Manhattan plots of conjunction and conditional 
−log10 (FDR) values for FTD (black) and FTD given AD (FTD|AD, red) and PD (FTD|PD, 
green). SNPs with conditional and conjunction −log10 FDR>1.3 (ie, FDR<0.05) are shown 
with large points. A black line around the large points indicates the most significant SNP in 
each LD block, and this SNP was annotated with the closest gene, which is listed above the 
symbols in each locus. For additional details, see online supplementary information. AD, 
Alzheimer’s disease; FTD, frontotemporal dementia; LD, linkage disequilibrium; PD, 
Parkinson’s disease.
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Figure 3. 
Forest plots for (A) rs6857 on chromosome 19 and (B) rs1358071 on chromosome 17.
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Figure 4. 
(A) MAPT-locus on chromosome 17. The two SNPs, rs1358071 and rs199528, are shared 
between FTD and PD. Either SNP is in LD with rs1052553 whose major allele (A) tags the 
H1 MAPT-haplotype. The major alleles of rs1358071 and rs199528 are also the effect 
alleles, and they are in LD with rs1052553 (r2=0.75 and 0.84, respectively). Thus, the effect 
at this locus is H1 driven. (B) APOE locus. The two haplotypes a and b are depicted. 
Haplotype a is the one driven by rs6857 with 13 SNPs in LD (r2~0.8; font color: blue). 
Haplotype b is the one driven by rs405509 with 10 SNPs in LD (r2~0.8; font color: black). 
Rs6857 and rs405509, and the respective haplotypes a and b, are in LE (r2~0.1). FTD, 
frontotemporal dementia; LD, linkage disequilibrium; LE, linkage equilibrium; PD, 
Parkinson’s disease.
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Table 1
Summary data from all GWAS used in the current study
Disease/trait
Total
N # SNPs Reference
Frontotemporal dementia (FTD)—
IFGC phase I
6462 6 026 384 16
Frontotemporal dementia (FTD)—
IFGC phase II
6466 Illumina NeuroX
Chip
16
Alzheimer’s disease (AD)—phase I 54 162 7 055 881 23
Parkinson’s disease (PD) 17 352 7 689 524 24
GWAS, genome-wide association studies; IFGC, International FTD-Genomics Consortium.
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Table 2
Overlapping loci between FTD, PD and AD at a conjunction FDR<0.05
SNP Position Chr
Location;
nearest gene
Associated
phenotype
Min Conj
FDR
FTD
p-value
Associated phenotype
p-value
Direction
of effect
rs7664889 77 087 704 4 Intronic; SCARB2 PD 4.84E-02 1.75E-04 8.88E-04 ++++
rs9268877 32 431 147 6 Intergenic; HLA-DRA PD 4.84E-02 1.04E-10 7.41E-04 ++++
rs676768 116 030 773 10 Intronic; VWA2 PD 4.27E-02 3.12E-04 6.14E-04 ++++
rs10784359 40 445 750 12 Intronic; SLC2A13 PD 3.26E-02 1.58E-04 7.47E-05 ++++
rs2893253 107 067 203 13 Intergenic; EFNB2 PD 3.55E-02 2.02E-04 1.11E-04 ++++
rs199528 44 843 136 17 Intronic; WNT3 PD 1.80E-02 4.09E-05 9.82E-16 ++++
rs1358071 43 803 189 17 Intronic; CRHR1 PD 2.02E-02 4.96E-05 7.76E-15 ++++
rs12964543 56 543 095 18 Intronic; ZNF532 PD 2.73E-02 1.12E-04 3.08E-04 ++++
rs405509 45 408 836 19 Intergenic; APOE AD 5.22E-03 1.25E-05 6.16E-70 ++++
AD, Alzheimer’s disease; FDR, false discovery rate; FTD, frontotemporal dementia; PD, Parkinson’s disease.
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